Deepinder Goyal responds to Temple wearable row as scientists demand regulatory scrutiny
Synopsis
Clinical scientists have declared 'zero evidence' for the core claims of Deepinder Goyal's ₹85,000 head-worn wearable Temple, demanding regulatory action. Goyal has fired back, insisting Temple is a 'fitness + AI device' — not a medical one — and that regulators, not social media, will have the final word. With a $54 million funding round and pre-orders already open, the classification battle could make or break the device's global rollout.
Key Takeaways
Clinical scientists reviewing Temple's website found 'zero evidence' that the device measures what it claims, demanding regulatory scrutiny.
Deepinder Goyal , founder of Eternal , defended Temple as a 'fitness + AI device' and denied making any medical claims.
Temple, priced at ₹85,000 , tracks two metrics — BrainFlow (relative brain circulation changes) and Entropy (a score of 1–250 ).
Pre-orders opened on 1 November ; deliveries are expected in roughly three months .
Goyal led a $54 million funding round for the startup and said fewer than 1% of units are expected to sell in India.
Eternal founder Deepinder Goyal on 9 November 2026 responded to a growing controversy surrounding his ₹85,000 head-worn wearable device, Temple, after clinical scientists raised fresh alarms about the device's claims and called on regulators to intervene. The rebuttal came as scientific reviewers said they found 'zero evidence' that Temple measures what its promotional material claims.
What the scientists found
Clinical scientists who reviewed the scientific material published on Temple's official website said the device is capable of capturing only heart rate and blood flow to the scalp through the temporal artery. They accused Goyal of allegedly misrepresenting the science behind the device and demanded that regulators scrutinise the claims being made around it. Their assessment was unambiguous: 'zero evidence' exists to demonstrate that Temple measures what it claims.
What Goyal said in response
Goyal acknowledged the criticism from the social media community and doctors, saying it gives him 'much needed clarity on what we need to explain better.' He maintained that social media is not the appropriate regulator for Temple. 'Wherever we need regulatory clearances, we will have them before we make any claim needing them,' he said.
In a detailed post, Goyal pushed back on the framing of Temple as a medical device. 'Temple is not made for India. It's made for the world. Please check the pricing. We don't expect any more than 1 per cent of Temples being sold in India. We didn't make any medical claim. Doctors primarily see things from a medical lens, so they see every claim as a medical claim,' he wrote.
He added: 'I repeat — Temple is strictly a fitness + AI device, and we've made no medical claims. Temple is not proven to diagnose or prevent any disease. It doesn't do anything which replaces the need for you to see a doctor. The main point of Temple is NOT Brain Flow. That's what we just started Temple for, and studies on Brain Flow are the first ones getting out.'
How Temple works and what it tracks
Temple is a head-worn wearable positioned on the side of the forehead. It promotes two key metrics: BrainFlow, which tracks relative changes in brain circulation, and Entropy, a score ranging from 1 to 250 that is meant to indicate how hard the body is working. Critics argue these metrics lack peer-reviewed validation, a concern the company has not yet directly addressed with published clinical data.
Funding, pricing, and rollout
Pre-orders for Temple opened on 1 November, with deliveries expected in approximately three months. Goyal led a $54 million funding round for the startup behind the device. At ₹85,000, the price point places Temple firmly in the premium consumer-tech segment, and Goyal has signalled that international markets — not India — are its primary audience.
The regulatory question
The core dispute hinges on how Temple is classified. If it makes health or physiological claims, it may fall under medical device regulations in key markets. Goyal's insistence that it is a 'fitness + AI device' is a significant legal and commercial distinction — one that regulators in the US, EU, and other jurisdictions may be asked to adjudicate. This comes amid broader global scrutiny of consumer wearables that blur the line between wellness gadgets and diagnostic tools. How regulators ultimately classify Temple could determine whether the device's core value propositions survive intact.
Point of View
But it sits uneasily alongside Temple's own promotional emphasis on BrainFlow, a metric that directly invokes brain physiology. Clinical scientists are right to flag the gap between marketing language and published evidence; the absence of peer-reviewed validation for the device's core metrics is a material weakness that neither a funding round nor a sharp social media response can paper over. The deeper issue is systemic: global regulators have consistently struggled to keep pace with consumer health-tech that uses wellness vocabulary to avoid medical-device oversight. Temple may well become a test case for how that boundary is drawn in markets far beyond India.
NationPress
9 Nov 2026
Frequently Asked Questions
What is the Temple wearable device and who made it?
Temple is a head-worn wearable device created by a startup founded by Deepinder Goyal , founder of Eternal . Priced at ₹85,000 , it is positioned on the side of the forehead and tracks two proprietary metrics — BrainFlow and Entropy — which the company describes as fitness and AI-driven indicators.
Why are clinical scientists criticising the Temple device?
Clinical scientists who reviewed Temple's published scientific material said they found 'zero evidence' that the device measures what it claims. They argue the hardware can capture only heart rate and scalp blood flow through the temporal artery, and have called on regulators to scrutinise the device's promotional claims.
Is Temple classified as a medical device?
Deepinder Goyal insists Temple is a 'strictly fitness + AI device' and that no medical claims have been made. He argues the device is not proven to diagnose or prevent any disease, and does not replace the need for a doctor. Whether regulators in key markets agree with that classification remains an open question.
How much funding has the Temple startup raised and when does it ship?
Goyal led a $54 million funding round for the startup behind Temple. Pre-orders opened on 1 November , with deliveries expected in approximately three months . Goyal has said the global market — not India — is the primary target, with fewer than 1% of units expected to sell domestically.
What happens next in the Temple controversy?
Regulators in key international markets may be called upon to determine whether Temple's claims require medical-device classification. Goyal has said the company will obtain all required regulatory clearances before making any claims that need them. The outcome could significantly shape the device's commercial viability and marketing language going forward.
